Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.97 |
| ▸ | TK2 | O00142 | 2/20 | 0.68 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.64 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.64 |
| ▸ | TK1 | P04183 | 2/20 | 0.62 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18032577 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL2056544 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL3412420 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL2579194 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL12315567 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL3389861 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL97335 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL2056540 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL97336 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 | |
| SCHEMBL5165189 | 1.00 | PYGM (0.97) | PYGMTK2P2RY6P2RY14TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS, INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | SONIC MASTER LTD (VG) | 2021-07-01 | — | — | US | disclosed |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | RIGEL PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-10933068-B2 | Modulators of DUX4 for regulation of muscle function | SONIC MASTER LIMITED (VG) | 2021-03-02 | — | — | US | disclosed |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | Rigel Pharmceuticals, Inc. (US) | 2020-11-10 | — | — | US | disclosed |
| CN-1625400-A | 2, 4-pyrimidinediamine compounds and uses thereof | RIGEL PHARMACEUTICALS INC (US) | 2005-06-08 | — | — | CN | disclosed |
| EP-1534286-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | Rigel Pharmaceuticals, Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050113398-A1 | Use of 5-halo or trifluoromethylpyrimidine-2,4-diamine compounds to treat proliferative diseases such as tumorgenic cancers | RIGEL PHARMACEUTICALS, INC. | 2005-05-26 | — | — | US | disclosed |
| WO-2005016893-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | MIDCAP FINANCIAL TRUST | 2005-02-17 | — | — | US | disclosed |
| WO-2005012294-A1 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS FOR USE IN THE TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES | RIGEL PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| EP-1471915-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | Rigel Pharmaceuticals, Inc. (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004014382-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | RIGEL PHARMACEUTICALS (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040029902-A1 | Antiinflamamtory agents | MIDCAP FINANCIAL TRUST | 2004-02-12 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210196723-A1 | Modulators of DUX4 for Regulation of Muscle Function | DDX21, MBNL1, MECP2 | PYGM 110/4885TK2 2053/4885P2RY6 4708/4885 |
| US-11230554-B2 | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds | SSB, TPMT, ADAR | PYGM 3643/4885TK2 286/4885P2RY6 234/4885 |
| US-11667611-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PYGM 2703/4885TK2 1152/4885P2RY6 2185/4885 |
| US-10933068-B2 | Modulators of DUX4 for regulation of muscle function | DDX21, MBNL1, MECP2 | PYGM 107/4885TK2 2044/4885P2RY6 4695/4885 |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PYGM 2923/4885TK2 1018/4885P2RY6 2598/4885 |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | PYGM 2923/4885TK2 1018/4885P2RY6 2598/4885 |
| US-20040029902-A1 | Antiinflamamtory agents | FCER2, FCGR1A, HNMT | PYGM 2277/4885TK2 940/4885P2RY6 111/4885 |
| US-20220073536-A1 | METHODS OF TREATING OR PREVENTING AUTOIMMUNE DISEASES WITH 2,4-PYRIMIDINEDIAMINE COMPOUNDS | SSB, TPMT, ADAR | PYGM 3844/4885TK2 248/4885P2RY6 223/4885 |
| US-20220098181-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | PYGM 2923/4885TK2 1018/4885P2RY6 2598/4885 |
| US-20050038243-A1 | Prevent immunoglobulin receptors signaling cascading; prevention diseases; drugs; antiinflammatory agents | FCER2, FCGR1A, FCGR2A | PYGM 3015/4885TK2 3755/4885P2RY6 42/4885 |
| US-11007193-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PYGM 3047/4885TK2 990/4885P2RY6 13/4885 |
| US-20050113398-A1 | Use of 5-halo or trifluoromethylpyrimidine-2,4-diamine compounds to treat proliferative diseases such as tumorgenic cancers | MKI67, DPYD, VHL | PYGM 4664/4885TK2 30/4885P2RY6 2177/4885 |
| US-10828301-B2 | 2,4-pyrimidinediamine compounds and their uses | FCER2, FCGR1A, FCGR2A | PYGM 3047/4885TK2 990/4885P2RY6 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.